Sacituzumab govitecan

CAS No. 1491917-83-9

Sacituzumab govitecan( —— )

Catalog No. M37126 CAS No. 1491917-83-9

Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, facilitates the delivery of SN-38. It demonstrates anticancer activity .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 1125 Get Quote
5MG 1547 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Sacituzumab govitecan
  • Note
    Research use only, not for human use.
  • Brief Description
    Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, facilitates the delivery of SN-38. It demonstrates anticancer activity .
  • Description
    Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Antibody-Drug Conjugates (ADCs)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1491917-83-9
  • Formula Weight
    160 KDa (Approximately)
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 25 mg/mL (Ultrasonic)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. ?
molnova catalog
related products
  • GTPγS tetralithium

    GTPγS tetralithium (Guanosine 5'-[γ-thio]triphosphate tetralithium) is a G-protein activator, a non-hydrolyzable GTP analog that protects proteins from proteolytic degradation.

  • Isogambogenic acid

    Isogambogenic acid inhibits angiogenesis and may be a viable drug candidate in anti-angiogenesis therapy.

  • 8,8-Bibaicalein

    8,8''-Bibaicalein is a natural product from Scutellaria baicalensis.